V
6.15
0.16 (2.67%)
| Previous Close | 5.99 |
| Open | 6.03 |
| Volume | 6,406 |
| Avg. Volume (3M) | 47,854 |
| Market Cap | 56,881,964 |
| Price / Sales | 2.67 |
| Price / Book | 238.54 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -236.41% |
| Diluted EPS (TTM) | -11.40 |
| Quarterly Revenue Growth (YOY) | -10.10% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | -53.66 M |
| Levered Free Cash Flow (TTM) | -32.56 M |
| Return on Assets (TTM) | -62.87% |
| Return on Equity (TTM) | -1,546.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Verrica Pharmaceuticals Inc. | Mixed | Bearish |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.67 |
|
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 44.90% |
| % Held by Institutions | 32.25% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |